Sung K Chiu

Dr. Sung K Chiu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
LCLaurence C Cheung
Laurence C Cheung
CACarlos Aya-Bonilla
Carlos Aya-Bonilla
MCMark Cruickshank
Mark Cruickshank
SCSung K Chiu
Sung K Chiu
VKVincent Kuek
Vincent Kuek
RKRishi S Kotecha
Rishi S Kotecha
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. KMT2A-rearranged infant ALL cells are characterized by an abundance of promoter hypermethylation and exhibit high BCL-2 expression, highlighting potential for therapeutic targeting. Here, we show that hypomethylating agents exhibit in vitro additivity when combined with most conventional chemotherapeutic agents. However, in a subset of samples an antagonistic effect was seen between several agents. This was most evident when hypomethylating agents were combined with methotrexate, with upregulation of ATP-binding cassette transporters identified as a potential mechanism. Single agent treatment with azacitidine and decitabine significantly prolonged in vivo survival in KMT2A-rearranged infant ALL xenografts. Treatment of KMT2A-rearranged infant ALL cell lines with azacitidine and decitabine led to differential genome-wide DNA methylation, changes in gene expression and thermal proteome profiling revealed the target protein-binding landscape of these agents. The selective BCL-2 inhibitor, venetoclax, exhibited in vitro additivity in combination with hypomethylating or conventional chemotherapeutic agents. The addition of venetoclax to azacitidine resulted in a significant in vivo survival advantage indicating the therapeutic potential of this combination to improve outcome for infants with KMT2A-rearranged ALL.

1 August 2019 in HemaSphere
Verified
Journal Article
Open access
VLVictoria Y. Ling
Victoria Y. Ling
JSJesslyn Saw
Jesslyn Saw
CTCedric S. Tremblay
Cedric S. Tremblay
SSStefan E. Sonderegger
Stefan E. Sonderegger
ETEmma Toulmin
Emma Toulmin
DCDavid J. Curtis
David J. Curtis
Supplemental Digital Content is available in the text

5 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SCSung K Chiu
Sung K Chiu
EFEmanuela Ferrari
Emanuela Ferrari
JOJoyce Oommen
Joyce Oommen
SMSebastien Malinge
Sebastien Malinge
LCLaurence C Cheung
Laurence C Cheung
RKRishi S Kotecha
Rishi S Kotecha
Background/Objectives: Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have high rates of relapse and poor survival compared with children. Few new therapies have been identified over the past twenty years. The aim of this study was to identify existing anti-cancer agents that have the potential to be repurposed for the treatment of infant ALL. Methods: Eight extensively characterized infant ALL cell lines were treated with 62 anti-neoplastic drugs in vitro to identify agents that exhibit significant cytotoxicity. From this screen, we selected the most effective and clinically translatable agent for further in vitro and in vivo assessment to determine the potential for use in the clinical setting. Results: Our anti-cancer drug screen revealed significant activity of dactinomycin across all infant ALL cell lines. Further in vitro testing identified low half-maximal inhibitory concentrations (IC50) across our infant ALL cell lines in the nanomolar range. Combination testing with the conventional chemotherapeutic agents currently used to treat infants with ALL demonstrated additivity with cytarabine. In vivo assessment of dactinomycin identified 36 μg/kg as the maximum tolerated dose, with unacceptable toxicities at higher dose treatment. Treatment using doses of 18 μg/kg administered either once or twice a week derived a small but significant survival benefit in patient-derived xenografts. Conclusions: Dactinomycin is extensively used for the treatment of solid tumors in children and has an acceptable safety profile when used to treat infants in this context. However, despite being readily translational and exhibiting promising in vitro cytotoxicity, dactinomycin showed limited efficacy in vivo and therefore does not represent a priority candidate for integrating into therapy for infants with ALL.

1 April 2026 in Blood Advances
Verified
Journal Article
Open access
SCSung K Chiu
Sung K Chiu
EFEliska Furlong
Eliska Furlong
AFAnnette Fox
Annette Fox
EMElizabeth J. McKinnon
Elizabeth J. McKinnon
SOStephany Sánchez Ovando
Stephany Sánchez Ovando
RKRishi S Kotecha
Rishi S Kotecha